SCHEMBL2356286

SCHEMBL2356286

CCNc1ccc(S(=O)(=O)C(F)(F)F)cc1N

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.78
ALDH1A1 P00352 4/20 0.58
TSHR P16473 1/20 0.49
HTT P42858 2/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
THRB P10828 1/20 0.48
HPGD P15428 1/20 0.48
GFER P55789 1/20 0.48
PLEC Q15149 1/20 0.48
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.40
ESPL1 Q14674 1/20 0.39
ALDH3A1 P30838 1/20 0.39
HRH4 Q9H3N8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KIF11 P52732 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2014382 0.81 ALDH1A1 (0.53) LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL5892015 0.80 LMNA (0.63) LMNAALDH1A1TSHRHTTMAPT
SCHEMBL3997818 0.80 ALDH1A1 (0.53) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL1457195 0.75 ALDH1A1 (1.00) LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL30370886 0.75 ALDH1A1 (1.00) LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL2789415 0.74 ALDH1A1 (0.66) LMNAALDH1A1HTTMAPTMEN1
SCHEMBL2788799 0.74 LMNA (0.62) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL13556573 0.74 ALDH1A1 (0.70) LMNAALDH1A1TSHRHTTMAPT
SCHEMBL356011 0.72 ALDH1A1 (0.54) LMNAALDH1A1TSHRHTTMAPT
SCHEMBL11312537 0.71 HTT (0.47) LMNAALDH1A1HTTMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536285-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF High Point Pharmaceuticals, LLC (US) 2012-12-26 EP disclosed
WO-2011103018-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF HIGH POINT PHARMACEUTICALS, LLC (US) 2011-08-25 WO disclosed
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
EP-1212296-B9 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN INC (US) 2006-05-10 EP disclosed
EP-1212296-B1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN INC (US) 2005-11-09 EP disclosed
US-20040138255-A1 Phosphate mimics and methods of treatment using phosphatease inhibitors SUGEN, INC. 2004-07-15 US disclosed
US-6596772-B1 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are SUGEN, INC. 2003-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138255-A1 Phosphate mimics and methods of treatment using phosphatease inhibitors PPP4C, PTPRO, PTPRS LMNA 4848/4885ALDH1A1 4477/4885TSHR 1928/4885
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases PTPA, PTPN1, PTPRS LMNA 4794/4885ALDH1A1 3296/4885TSHR 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.